Pfizer
Pfizer Reports 27 Percent Oncology Growth in Q4, Touts Progress in ADC and Breast Cancer Trials
Premium
The firm recorded Q4 oncology revenues of $4.06 billion compared to $3.19 billion in the same period in 2023.
Pfizer's Breast Cancer Drug Ibrance on CMS List for Next Round of IRA Price Negotiations
Although Pfizer is not among the drugmakers suing the government to block negotiations, it has said the program will hinder drug R&D and innovation.
JP Morgan Healthcare Conference, Day 1: Vertex, Bristol Myers Squibb, Gilead, Sarepta, and More
On the first day, Vertex discussed regulatory plans for a kidney disease drug, BMS and Merck talked about pipeline diversification, and Gilead offered updates on anito-cel.
Sangamo Regains Rights to Hemophilia A Gene Therapy After Pfizer Ends Partnership
Sangamo is seeking new partners to continue advancing giroctocogene fitelparvovec, which reported positive Phase III results this year.
FDA Approves Pfizer's Braftovi With Eli Lilly's Erbitux, Chemo in Colorectal Cancer
The agency granted accelerated approval to the regimen as a frontline option for advanced, BRAF V600E-mtuated tumors based on the BREAKWATER trial.